Drug Approval | May 18, 2025
EBITDA before special items decreases to €4.08 billion (7.4%)
Bayer expects 2025 to be the most difficult year of its turnaround
The product will be launched in Q1FY26
Rivaroxaban Tablets USP, 2.5 mg, is bioequivalent to Xarelto® Tablets, 2.5 mg of Janssen Pharmaceuticals
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
The company has received five final approvals
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Subscribe To Our Newsletter & Stay Updated
